🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Multimodal Survival Prediction Model for Colorectal Liver Metastases Post-Operation

Recruitingn/aAges 18 Years - 80 YearsAllAnhui Provincial Hospital
NCT07830576 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The purpose of this study is to construct and validate a multimodal survival prediction model by integrating 3D radiomics features derived from preoperative magnetic resonance imaging (MRI) with systemic clinical baseline indicators for patients with colorectal liver metastases (CRLM) after surgery. By combining micro-level radiomics signatures reflecting tumor micro-heterogeneity with macro-level clinical parameters (such as liver function and tumor biomarkers), the study aims to accurately evaluate individual post-operative prognostic risks. This quantitative tool will provide reliable decision support for clinicians to customize post-operative follow-up and personalized adjuvant treatment strategies.

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: Age \>= 18 years old. Confirmed diagnosis of colorectal cancer with liver metastases (CRLM). Underwent surgical resection for colorectal liver metastases. Preoperative liver magnetic resonance imaging (MRI) was performed with high-quality images available for 3D radiomics feature extraction. Complete baseline clinical, laboratory, and post-operative follow-up survival data. Exclusion Criteria: Patients who received local ablation only (such as radiofrequency ablation) without surgical resection. Preoperative MRI images with severe artifacts or poor quality that prevent high-throughput radiomics analysis. Concurrent history of other primary malignant neoplasms. Missing key clinical variables or lost to follow-up immediately after surgical intervention.
💊

What it tests

  • Multimodal Predictive Evaluation
📍

Where

1 site
The First Affiliated Hospital of University of Science and Technology of China
Hefei, China
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy